1 Great Dividend You Can Buy Right Now

Shareholders in this diagnostics company have witnessed their dividend grow by 340% over the past decade, and that could be just the tip of the iceberg.

Mar 21, 2014 at 12:05PM

Dividend stocks are everywhere, but many just downright stink. In some cases, the business model is in serious jeopardy, or the dividend itself isn't sustainable. In others, the dividend is so low, it's not even worth the paper your check is printed on. A solid dividend strikes the right balance of growth, value, and sustainability.

Today we're going to look at one dividend-paying company that you can put in your portfolio for the long term without too much concern. This isn't to say that these stocks don't share the same macro risks that other companies have, but they are a step above your common grade of dividend stock. Check out the previous selection.

This week, we'll turn our attention to molecular diagnostics and diagnostic information services provider Quest Diagnostics (NYSE:DGX) to discover why its long-term outlook and growing dividend could be an income investor's dream come true.

Obamacare: friend or foe?
As we often do when looking at potentially intriguing dividend plays, we'll start off by examining the risks associated with Quest Diagnostics. There is perhaps no greater source of uncertainty when it comes to Quest Diagnostics' business than the "Obamacare" health care reform law.

Dna Test

Source: James Tourtellotte, Wikimedia Commons.

On one hand, with the individual mandate requiring citizens to purchase health insurance or face a penalty that's the greater of $95 or 1% of their annual income in 2014, it seems reasonable that increased preventive visits to the doctor may result in more diagnostic tests being ordered. While this could be true, the early reality based on proposals from the Centers for Medicare and Medicaid Services, or CMS, is that Medicare funding for diagnostic tests is going to slowly decline over the coming years. Although Quest Diagnostics derives its revenue from a number of sources, Medicare is indeed one of them. This means that Quest's bottom line could take a hit if CMS continues to scale back its Medicare reimbursements.

We've seen evidence of this in the forecasts of both Quest and its slightly larger rival by market value Laboratory Corp. of America (NYSE: LH). Quest was forced to drop its full-year earnings forecast in October due to Medicare cuts, while Laboratory Corp. of America similarly trimmed its guidance in December.

Competition is another concern for Quest, with some of its peers buying their way to growth in what has been a slow-growth industry since the recession.

Agilent Technologies (NYSE:A), for instance, purchased Danish cancer diagnostics company Dako in 2012 for a whopping $2.2 billion in an effort to grow its life sciences business. The deal made further sense given that Dako's product line complemented Agilent's existing product portfolio.

Myriad Genetics (NASDAQ:MYGN), while relying on its deep diagnostic pipeline, has also turned to acquisitions to drive top and bottom-line growth. Myriad announced last month the $270 million purchase of privately held Crescendo Biosciences in order to get hold of the company's rheumatoid arthritis test. 

Ultimately, increased competition for similar disease diagnostic tests could drive down prices and hurt Quest's margins.

The promise of Quest Diagnostics
Still, there are a number of long-term positives that should fuel Quest Diagnostics higher.

First, the baby boomer population is starting to retire, meaning that an increase in diagnostic tests and medical care is likely around the corner. With life expectancies on the rise in the U.S. and one of the biggest cancer risk factors being old age, there's a good chance that diagnostic tests will play a crucial role in personalizing cancer treatments in the coming decade.

Second, despite worries that CMS will continue to decrease Medicare reimbursement rates, I would remind investors that Quest still receives a sizable portion of its revenue from insurers and individual payers. While that does leave it exposed to further reimbursement cuts from its Medicare business it also gives the company an opportunity to more than make up the difference in volume if more newly insured people get preventive-care checkups.

Third, consolidation within the sector only reinforces the notion that diagnostic tests may be about to become the next big thing in personalized medicine. In early February Thermo Fisher Scientific (NYSE:TMO) completed its mammoth $13.6 billion acquisition of Life Technologies in order to acquire its genome analysis line of products. Big deals like this signal the willingness of larger companies to take on risks, and also that there may be a lot of upside potential yet to come within the sector. 

Finally, Quest has also been delivered a key win in recent months thanks to a June 2013 ruling by the U.S. Supreme Court that allowed it to introduce a competing BRCA 1/BRCA 2 gene test to Myriad Genetics' BRACAnalysis diagnostic test.

Show me the money!
The true allure of Quest Diagnostics could be its consistent cash flow potential and growing dividend. The chart below shows that Quest doesn't have any consistent rhyme or reason regarding when it raises its dividend, but it has nonetheless boosted its payout by a substantial 340% since 2004. 

G
Source: Nasdaq.com, Assumes $0.33/quarter payment for remainder of 2014. 

Quest today yields 2.5%, which should begin to put it on an income investor's radar. Furthermore, I consider its dividend incredibly secure given that its payout ratio only equates to about 33% of its projected fiscal 2014 earnings per share. This leaves plenty of opportunity for this dividend to grow, as well as the ability for Quest to use its cash flow to pay down its existing debt balance of $3.37 billion. It could also use its cash flow to look for additional earnings-accretive acquisitions.

At less than 13 times forward earnings, with an impressive track record of dividend growth, and holding a bright future, Quest looks like a dividend stock you can buy right now.

Nine top dividend-paying stocks income-seeking investors will want to acquaint themselves with
One of the dirty secrets that few finance professionals will openly admit is the fact that dividend stocks as a group handily outperform their non-dividend paying brethren. The reasons for this are too numerous to list here, but you can rest assured that it's true. However, knowing this is only half the battle. The other half is identifying which dividend stocks in particular are the best. With this in mind, our top analysts put together a free list of nine high-yielding stocks that should be in every income investor's portfolio. To learn the identity of these stocks instantly and for free, all you have to do is click here now.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool recommends Laboratory Corp. of America, Quest Diagnostics, and Thermo Fisher Scientific. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers